Elevance Health Inc (NYSE: ELV) has reported E.P.S. of $4.36 for its third fiscal quarter (ending September 30) versus $5.48 for the same period a year ago — a decline of -20%. This result fell short of the consensus estimate of $9.71 by $-5.35. For the latest four quarters through September 30, E.P.S. were $27.46 versus $25.33 for the same period a year ago — an increase of 8%.
Recent Price Action
Elevance Health Inc (NYSE: ELV) stock suffered a major decline of -10.6% on 10/17/24. The shares closed at $444.35. Moreover, this decline was accompanied by exceptionally high trading volume at 761% of normal. The stock has performed in line with the market over the last nine months and has declined -10.0% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to be above the cost of capital, ELV is expected to continue to be a major Value Builder.
Elevance Health has a current Value Trend Rating of C (High Neutral). The Value Trend Rating reflects consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Elevance Health has a neutral Appreciation Score of 51 and a slightly positive Power Rating of 70, resulting in the High Neutral Value Trend Rating.
Rating Review
In light of this new information and highly negative price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment